CoChat

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial

Open access

Abstract

BACKGROUND: Nutrition is an important modifiable risk factor in Alzheimer's disease. Previous trials of the multinutrient Fortasyn Connect showed benefits in mild Alzheimer's disease dementia. LipiDiDiet investigated the effects of Fortasyn Connect on cognition and related measures in prodromal Alzheimer's disease. Here, we report the 24-month results of the trial. METHODS: LipiDiDiet was a 24-month randomised, controlled, double-blind, parallel-group, multicentre trial (11 sites in Finland, Germany, the Netherlands, and Sweden), with optional 12-month double-blind extensions. The trial enrolled individuals with prodromal Alzheimer's disease, defined according to the International Working Group (IWG)-1 criteria. Participants were randomly assigned (1:1) to active product (125 mL once-a-day drink containing Fortasyn Connect) or control product. Randomisation was computer-generated centrally in blocks of four, stratified by site. All study personnel and participants were masked to treatment assignment. The primary endpoint was change in a neuropsychological test battery (NTB) score. Analysis was by modified intention to treat. Safety analyses included all participants who consumed at least one study product dose. This trial is registered with the Dutch Trial Register, number NTR1705. FINDINGS: Between April 20, 2009, and July 3, 2013, 311 of 382 participants screened were randomly assigned to the active group (n=153) or control group (n=158). Mean change in NTB primary endpoint was -0·028 (SD 0·453) in the active group and -0·108 (0·528) in the control group; estimated mean treatment difference was 0·098 (95% CI -0·041 to 0·237; p=0·166). The decline in the control group was less than the prestudy estimate of -0·4 during 24 months. 66 (21%) participants dropped out of the study. Serious adverse events occurred in 34 (22%) participants in the active group and 30 (19%) in control group (p=0·487), none of which were regarded as related to the study intervention. INTERPRETATION: The intervention had no significant effect on the NTB primary endpoint over 2 years in prodromal Alzheimer's disease. However, cognitive decline in this population was much lower than expected, rendering the primary endpoint inadequately powered. Group differences on secondary endpoints of disease progression measuring cognition and function and hippocampal atrophy were observed. Further study of nutritional approaches with larger sample sizes, longer duration, or a primary endpoint more sensitive in this pre-dementia population, is needed. FUNDING: European Commission 7th Framework Programme.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(17)30332-0

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Trial profile *Rescue medication was defined as the use of active product or approved Alzheimer's disease medication after progression to dementia. †All randomly assigned participants, excluding visit data after the start of rescue medication. ‡Respective visits of participants were additionally excluded in cases of major protocol deviations; number based on participants with at least one follow-up visit in the per-protocol dataset.
Figure 1 Trial profile *Rescue medication was defined as the use of active product or approved Alzheimer's disease medication after progression to dementia. †All randomly assigned participants, excluding visit data after the start of rescue medication. ‡Respective visits of participants were additionally excluded in cases of major protocol deviations; number based on participants with at least one follow-up visit in the per-protocol dataset.CC BY · PubMed Central
Figure 2 Changes in main endpoints during the 24-month intervention (A) NTB primary endpoint. (B) NTB memory domain. (C) CDR-SB. (D) MRI total hippocampal volume. (E) MRI ventricular volume. (F) CDR-SB in subgroups defined by baseline MMSE. Data are observed mean change from baseline; error bars are SE. Sample size by baseline MMSE subgroup (control/active): ≥24: mITT 117/106 (PP 96/89), ≥25: 104/91 (86/75), ≥26: 95/79 (78/66), ≥27: 77/63 (66/53), ≥28: 55/43 (48/37), ≥29 29/21 (24/19). CDR-SB=clinical dementia rating-sum of boxes. mITT=modified intention-to-treat analysis. MMSE=Mini-Mental State Examination. NTB=neuropsychological test battery. PP=per-protocol analysis.
Figure 2 Changes in main endpoints during the 24-month intervention (A) NTB primary endpoint. (B) NTB memory domain. (C) CDR-SB. (D) MRI total hippocampal volume. (E) MRI ventricular volume. (F) CDR-SB in subgroups defined by baseline MMSE. Data are observed mean change from baseline; error bars are SE. Sample size by baseline MMSE subgroup (control/active): ≥24: mITT 117/106 (PP 96/89), ≥25: 104/91 (86/75), ≥26: 95/79 (78/66), ≥27: 77/63 (66/53), ≥28: 55/43 (48/37), ≥29 29/21 (24/19). CDR-SB=clinical dementia rating-sum of boxes. mITT=modified intention-to-treat analysis. MMSE=Mini-Mental State Examination. NTB=neuropsychological test battery. PP=per-protocol analysis.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Cited by

See all 242

Metadata

Authors
Soininen, H., Solomon, A., Visser, P. J., Hendrix, S. B., Blennow, K., Kivipelto, M., Hartmann, T., Hallikainen, I., Hallikainen, M., Helisalmi, S., Lappalainen, T., Liu, Y., Paajanen, T., Wahlund, L.-O., Freund-Levi, Y., Andreasen, N., Hagman, G., Lindblom, S., Fassbender, K., Riemenschneider, M., Grimm, M. O., Klees-Rollmann, A., Luley, M., Lyros, E., Schomburg, R., Kennel, J., Ramelli, D., Frölich, L., Hausner, L., Laske, C., Leyhe, T., Mychajliw, C., Koehler, N., Schiekofer, S., Klünemann, H., Schröder, J., Lütjohann, D., Scheltens, P., van Rossum, I., Scheltens, N., Bertens, D., ten Kate, M., Barkhof, F., Henselmans, J. M., Roks, G., van Hees, A. M., & Ellison, N.
Affiliations
  • University of Eastern Finland (FI)
  • Karolinska University Hospital (SE)
  • Maastricht University (NL)
  • Sahlgrenska University Hospital (SE)
  • Saarland University (DE)
Corresponding author
Soininen, Hilkka
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2017-12
Volume
16
Issue
12
Pages
965-975
ISSN
1474-4422 (ISSN-L)
OpenAlex
W2766767762
Cited by
241
References
39
Citations by year
2026: 13 · 2025: 20 · 2024: 27 · 2023: 25 · 2022: 30 · 2021: 30 · 2020: 36 · 2019: 32 · 2018: 25 · 2017: 2
FWCI
21.32
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet Neurology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UEF eRepo (University of Eastern Finland) (submittedVersion, cc-by)
  • Research Publications (Maastricht University) (submittedVersion, cc-by)
  • UCL Discovery (University College London) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion)
  • Research Publications (Maastricht University) (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
Funders
  • EU Joint Programme – Neurodegenerative Disease Research
  • European Commission (211696)
  • Royal Swedish Academy of Sciences
  • Academy of Finland
  • Kommunfullmäktige, Stockholms Stad
  • Karolinska Institutet
  • Kuopion Yliopistollinen Sairaala
  • Center for Innovative Medicine
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
Keywords
prodromal Alzheimer's disease, cognitive decline, neuropsychological test battery, long-term intervention, dietary intervention, adverse events, dementia prevention, cognitive preservation, vitamin B12
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Docosahexaenoic Acids, Double-Blind Method, Female, Humans, Male, Middle Aged, Phospholipids, Eicosapentaenoic Acid, Outcome Assessment, Health Care, Prodromal Symptoms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial. https://app.cochat.ai/papers/10.1016/s1474-4422(17)30332-0
The paper
Soininen, H., Solomon, A., Visser, P. J., Hendrix, S. B., Blennow, K., Kivipelto, M., Hartmann, T., Hallikainen, I., Hallikainen, M., Helisalmi, S., Lappalainen, T., Liu, Y., Paajanen, T., Wahlund, L.-O., Freund-Levi, Y., Andreasen, N., Hagman, G., Lindblom, S., Fassbender, K., . . . Ellison, N. (2017). 24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(17)30332-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.